Landmark MRSA (methicillin-resistant Staphylococcus aureus) damages case piles the pressure on UK NHS:
This article was originally published in Clinica
Executive Summary
A UK patient has won the first ever case for compensation from the National Health Service for contracting methicillin-resistant Staphylococcus aureus (MRSA), putting renewed pressure on the NHS to ensure it implements the applicable control measures. The case at the Princess of Wales Hospital in Bridgend, South Wales, occurred in February 2001 following a hip replacement operation. The infection resulted in the removal of the implanted hip; later bone deterioration precluded a further replacement, leaving the patient permanently disabled. The hospital reached a settlement for undisclosed "substantial damages", admitting some failings in relation to the prevention and treatment of the infection; previous compensation cases had hinged on admissions of inadequate treatment.
You may also be interested in...
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.